Annovis Bio, Inc.
ANVSDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How ANVS's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
buntanetap/posiphen | Phase 3 | Parkinson's Disease, Idiopathic | - | - |
Posiphen | Phase 2 | Alzheimer's Disease | - | - |
Frequently asked questions
What is in Annovis Bio, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Annovis Bio, Inc.'s (ANVS) pipeline across Phase 3, Phase 2. Its lead program is buntanetap/posiphen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Annovis Bio, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Annovis Bio, Inc. (ANVS) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ANVS biotech catalysts?→
Add ANVS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Annovis Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.